Stock & Company Details
Bausch + Lomb Corp $BLCO
Price:
N/A
N/A
357M
$6.1B
52 Week High:
N/A
10 Day Average Volume:
N/A
-35.59
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Services
BLCO technical indicators
Latest Bausch + Lomb Corp (BLCO) indicator readings as of 2026-10-09.
BLCO's 14-day RSI is 53.6, in neutral territory. At $17.30 it is trading 3.9% above its 200-day moving average of $16.65, and above its 50-day average of $17.16. Price sits in the middle of its Bollinger Bands ($16.66 to $17.50). ADX reads 8.5, indicating a range-bound market rather than a trend.
BLCO backtested strategy results
How 4 rule-based strategies performed on Bausch + Lomb Corp (BLCO) over recent history, last backtested 2026-10-08. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +52.8% | 63% | 8 | -24.0% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -43.8% | 25% | 20 | -48.0% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -52.6% | 27% | 22 | -55.3% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +77.4% | 72% | 18 | -23.2% |
Overview
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Finance Bot
Ask your questions
Start by typing a question below.
